Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1996 Sep;72(851):513–518. doi: 10.1136/pgmj.72.851.513

Homocystinuria: what about mild hyperhomocysteinaemia?

M van den Berg 1, G H Boers 1
PMCID: PMC2398569  PMID: 8949585

Abstract

Hyperhomocysteinaemia is associated with an increased risk of atherosclerotic vascular disease and thromboembolism, in both men and women. A variety of conditions can lead to elevated homocysteine levels, but the relation between high levels and vascular disease is present regardless of the underlying cause. Pooled data from a large number of studies demonstrate that mild hyperhomocysteinaemia after a standard methionine load is present in 21% of young patients with coronary artery disease, in 24% of patients with cerebrovascular disease, and in 32% of patients with peripheral vascular disease. From such data an odds ratio of 13.0 (95% confidence interval 5.9 to 28.1), as an estimate of the relative risk of vascular disease at a young age, can be calculated in subjects with an abnormal response to methionine loading. Furthermore, mild hyperhomo-cysteinaemia can lead to a two- or three-fold increase in the risk of recurrent venous thrombosis. Elevated homocysteine levels can be reduced to normal in virtually all cases by simple and safe treatment with vitamin B6, folic acid, and betaine, each of which is involved in methionine metabolism. A clinically beneficial effect of such an intervention, currently under investigation, would make large-scale screening for this risk factor mandatory.

Full text

PDF
513

Images in this article

514Figure 2
on p.514

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agardh C. D., Agardh E., Andersson A., Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1994 Dec;54(8):637–641. doi: 10.3109/00365519409087544. [DOI] [PubMed] [Google Scholar]
  2. Boers G. H., Fowler B., Smals A. G., Trijbels F. J., Leermakers A. I., Kleijer W. J., Kloppenborg P. W. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet. 1985;69(2):164–169. doi: 10.1007/BF00293290. [DOI] [PubMed] [Google Scholar]
  3. Boers G. H. Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease. Neth J Med. 1994 Jul;45(1):34–41. [PubMed] [Google Scholar]
  4. Bostom A. G., Jacques P. F., Nadeau M. R., Williams R. R., Ellison R. C., Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis. 1995 Jul;116(1):147–151. doi: 10.1016/0021-9150(95)05529-6. [DOI] [PubMed] [Google Scholar]
  5. Brattström L., Israelsson B., Norrving B., Bergqvist D., Thörne J., Hultberg B., Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990 Feb;81(1):51–60. doi: 10.1016/0021-9150(90)90058-q. [DOI] [PubMed] [Google Scholar]
  6. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155. doi: 10.1056/NEJM199104253241701. [DOI] [PubMed] [Google Scholar]
  7. Engbersen A. M., Franken D. G., Boers G. H., Stevens E. M., Trijbels F. J., Blom H. J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995 Jan;56(1):142–150. [PMC free article] [PubMed] [Google Scholar]
  8. Franken D. G., Boers G. H., Blom H. J., Trijbels F. J., Kloppenborg P. W. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994 Mar;14(3):465–470. doi: 10.1161/01.atv.14.3.465. [DOI] [PubMed] [Google Scholar]
  9. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J., den Heijer M., Kluijtmans L. A., van den Heuvel L. P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–113. doi: 10.1038/ng0595-111. [DOI] [PubMed] [Google Scholar]
  10. Goyette P., Sumner J. S., Milos R., Duncan A. M., Rosenblatt D. S., Matthews R. G., Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994 Jun;7(2):195–200. doi: 10.1038/ng0694-195. [DOI] [PubMed] [Google Scholar]
  11. Guttormsen A. B., Schneede J., Fiskerstrand T., Ueland P. M., Refsum H. M. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr. 1994 Oct;124(10):1934–1941. doi: 10.1093/jn/124.10.1934. [DOI] [PubMed] [Google Scholar]
  12. Harker L. A., Ross R., Slichter S. J., Scott C. R. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976 Sep;58(3):731–741. doi: 10.1172/JCI108520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harker L. A., Slichter S. J., Scott C. R., Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974 Sep 12;291(11):537–543. doi: 10.1056/NEJM197409122911101. [DOI] [PubMed] [Google Scholar]
  14. Hultberg B., Agardh E., Andersson A., Brattström L., Isaksson A., Israelsson B., Agardh C. D. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1991 May;51(3):277–282. doi: 10.3109/00365519109091615. [DOI] [PubMed] [Google Scholar]
  15. Kang S. S., Wong P. W., Bock H. G., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet. 1991 Mar;48(3):546–551. [PMC free article] [PubMed] [Google Scholar]
  16. Kang S. S., Wong P. W., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991 Mar;48(3):536–545. [PMC free article] [PubMed] [Google Scholar]
  17. Kozich V., Kraus E., de Franchis R., Fowler B., Boers G. H., Graham I., Kraus J. P. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level. Hum Mol Genet. 1995 Apr;4(4):623–629. doi: 10.1093/hmg/4.4.623. [DOI] [PubMed] [Google Scholar]
  18. Malinow M. R. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994 Dec;236(6):603–617. doi: 10.1111/j.1365-2796.1994.tb00854.x. [DOI] [PubMed] [Google Scholar]
  19. Malinow M. R., Nieto F. J., Szklo M., Chambless L. E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 1993 Apr;87(4):1107–1113. doi: 10.1161/01.cir.87.4.1107. [DOI] [PubMed] [Google Scholar]
  20. Miller J. W., Ribaya-Mercado J. D., Russell R. M., Shepard D. C., Morrow F. D., Cochary E. F., Sadowski J. A., Gershoff S. N., Selhub J. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr. 1992 Jun;55(6):1154–1160. doi: 10.1093/ajcn/55.6.1154. [DOI] [PubMed] [Google Scholar]
  21. Mudd S. H., Skovby F., Levy H. L., Pettigrew K. D., Wilcken B., Pyeritz R. E., Andria G., Boers G. H., Bromberg I. L., Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985 Jan;37(1):1–31. [PMC free article] [PubMed] [Google Scholar]
  22. Mölgaard J., Malinow M. R., Lassvik C., Holm A. C., Upson B., Olsson A. G. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992 Mar;231(3):273–279. doi: 10.1111/j.1365-2796.1992.tb00535.x. [DOI] [PubMed] [Google Scholar]
  23. Refsum H., Ueland P. M. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci. 1990 Oct;11(10):411–416. doi: 10.1016/0165-6147(90)90148-2. [DOI] [PubMed] [Google Scholar]
  24. Sardharwalla I. B., Fowler B., Robins A. J., Komrower G. M. Detection of heterozygotes for homocystinuria. Study of sulphur-containing amino acids in plasma and urine after L-methionine loading. Arch Dis Child. 1974 Jul;49(7):553–559. doi: 10.1136/adc.49.7.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Selhub J., Jacques P. F., Bostom A. G., D'Agostino R. B., Wilson P. W., Belanger A. J., O'Leary D. H., Wolf P. A., Schaefer E. J., Rosenberg I. H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995 Feb 2;332(5):286–291. doi: 10.1056/NEJM199502023320502. [DOI] [PubMed] [Google Scholar]
  26. Selhub J., Jacques P. F., Wilson P. W., Rush D., Rosenberg I. H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993 Dec 8;270(22):2693–2698. doi: 10.1001/jama.1993.03510220049033. [DOI] [PubMed] [Google Scholar]
  27. Shin H. K., Linkswiler H. M. Tryptophan and methionine metabolism of adult females as affected by vitamin B-6 deficiency. J Nutr. 1974 Oct;104(10):1348–1355. doi: 10.1093/jn/104.10.1348. [DOI] [PubMed] [Google Scholar]
  28. Stamler J. S., Osborne J. A., Jaraki O., Rabbani L. E., Mullins M., Singel D., Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993 Jan;91(1):308–318. doi: 10.1172/JCI116187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Stampfer M. J., Malinow M. R., Willett W. C., Newcomer L. M., Upson B., Ullmann D., Tishler P. V., Hennekens C. H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877–881. [PubMed] [Google Scholar]
  30. Starkebaum G., Harlan J. M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986 Apr;77(4):1370–1376. doi: 10.1172/JCI112442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Taylor L. M., Jr, DeFrang R. D., Harris E. J., Jr, Porter J. M. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991 Jan;13(1):128–136. doi: 10.1067/mva.1991.24913. [DOI] [PubMed] [Google Scholar]
  32. Tsai J. C., Perrella M. A., Yoshizumi M., Hsieh C. M., Haber E., Schlegel R., Lee M. E. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6369–6373. doi: 10.1073/pnas.91.14.6369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ueland P. M., Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989 Nov;114(5):473–501. [PubMed] [Google Scholar]
  34. Van den Berg M., Boers G. H., Franken D. G., Blom H. J., Van Kamp G. J., Jakobs C., Rauwerda J. A., Kluft C., Stehouwert C. D. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995 Mar;25(3):176–181. doi: 10.1111/j.1365-2362.1995.tb01545.x. [DOI] [PubMed] [Google Scholar]
  35. Verhoef P., Hennekens C. H., Malinow M. R., Kok F. J., Willett W. C., Stampfer M. J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994 Oct;25(10):1924–1930. doi: 10.1161/01.str.25.10.1924. [DOI] [PubMed] [Google Scholar]
  36. de Groot P. G., Willems C., Boers G. H., Gonsalves M. D., van Aken W. G., van Mourik J. A. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest. 1983 Oct;13(5):405–410. doi: 10.1111/j.1365-2362.1983.tb00121.x. [DOI] [PubMed] [Google Scholar]
  37. den Heijer M., Blom H. J., Gerrits W. B., Rosendaal F. R., Haak H. L., Wijermans P. W., Bos G. M. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995 Apr 8;345(8954):882–885. doi: 10.1016/s0140-6736(95)90008-x. [DOI] [PubMed] [Google Scholar]
  38. van den Berg M., Franken D. G., Boers G. H., Blom H. J., Jakobs C., Stehouwer C. D., Rauwerda J. A. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg. 1994 Dec;20(6):933–940. doi: 10.1016/0741-5214(94)90230-5. [DOI] [PubMed] [Google Scholar]
  39. von Eckardstein A., Malinow M. R., Upson B., Heinrich J., Schulte H., Schönfeld R., Köhler E., Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994 Mar;14(3):460–464. doi: 10.1161/01.atv.14.3.460. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES